{"id":"https://openalex.org/W4414439823","doi":"https://doi.org/10.1016/j.ajpc.2025.101131","title":"SAFETY AND EFFICACY OF OBICETRAPIB IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA","display_name":"SAFETY AND EFFICACY OF OBICETRAPIB IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA","publication_year":2025,"publication_date":"2025-09-01","ids":{"openalex":"https://openalex.org/W4414439823","doi":"https://doi.org/10.1016/j.ajpc.2025.101131"},"language":"en","primary_location":{"id":"doi:10.1016/j.ajpc.2025.101131","doi":"https://doi.org/10.1016/j.ajpc.2025.101131","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ajpc.2025.101131","pdf_url":null,"source":{"id":"https://openalex.org/S4210223033","display_name":"American Journal of Preventive Cardiology","issn_l":"2666-6677","issn":["2666-6677"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","jufo-1","ki-jl-1","norway-1","oarl","poland-20","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Preventive Cardiology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1016/j.ajpc.2025.101131","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Andy Hsieh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405272097","display_name":"NewAmsterdam Pharma (Netherlands)","ror":"https://ror.org/03jdnwh76","country_code":"NL","type":"company","lineage":["https://openalex.org/I4405272097"]}],"countries":["NL"],"is_corresponding":true,"raw_author_name":"Andy Hsieh","raw_affiliation_strings":["New Amsterdam Pharma"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"New Amsterdam Pharma","institution_ids":["https://openalex.org/I4405272097"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Stephen Nicholls","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I56590836","display_name":"Monash University","ror":"https://ror.org/02bfwt286","country_code":"AU","type":"education","lineage":["https://openalex.org/I56590836"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Stephen Nicholls","raw_affiliation_strings":["Monash University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Monash University","institution_ids":["https://openalex.org/I56590836"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059089207","display_name":"Adam J. Nelson","orcid":"https://orcid.org/0000-0003-0990-2548","observed_orcids":["https://orcid.org/0000-0003-0990-2548"]},"institutions":[{"id":"https://openalex.org/I56590836","display_name":"Monash University","ror":"https://ror.org/02bfwt286","country_code":"AU","type":"education","lineage":["https://openalex.org/I56590836"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Adam J Nelson","raw_affiliation_strings":["Monash University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Monash University","institution_ids":["https://openalex.org/I56590836"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079365240","display_name":"Marc Ditmarsch","orcid":"https://orcid.org/0000-0002-2970-1893","observed_orcids":["https://orcid.org/0000-0002-2970-1893"]},"institutions":[{"id":"https://openalex.org/I4405272097","display_name":"NewAmsterdam Pharma (Netherlands)","ror":"https://ror.org/03jdnwh76","country_code":"NL","type":"company","lineage":["https://openalex.org/I4405272097"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Marc Ditmarsch","raw_affiliation_strings":["New Amsterdam Pharma"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"New Amsterdam Pharma","institution_ids":["https://openalex.org/I4405272097"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077848934","display_name":"John J.P. Kastelein","orcid":"https://orcid.org/0000-0003-2018-4532","observed_orcids":["https://orcid.org/0000-0003-2018-4532"]},"institutions":[{"id":"https://openalex.org/I4405272097","display_name":"NewAmsterdam Pharma (Netherlands)","ror":"https://ror.org/03jdnwh76","country_code":"NL","type":"company","lineage":["https://openalex.org/I4405272097"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"John J.P. Kastelein","raw_affiliation_strings":["New Amsterdam Pharma"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"New Amsterdam Pharma","institution_ids":["https://openalex.org/I4405272097"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052604218","display_name":"Christie Mitchell Ballantyne","orcid":"https://orcid.org/0000-0002-6432-1730","observed_orcids":["https://orcid.org/0000-0002-6432-1730"]},"institutions":[{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christie M. Ballantyne","raw_affiliation_strings":["Baylor College of Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Baylor College of Medicine","institution_ids":["https://openalex.org/I181547552"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006206326","display_name":"Kausik Kumar Ray","orcid":"https://orcid.org/0000-0003-0508-0954","observed_orcids":["https://orcid.org/0000-0003-0508-0954","https://orcid.org/0000-0002-7166-060X"]},"institutions":[{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Kausik K. Ray","raw_affiliation_strings":["Imperial College of London"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Imperial College of London","institution_ids":["https://openalex.org/I47508984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048673551","display_name":"Ann Marie N\u00e1var","orcid":"https://orcid.org/0000-0002-6197-9860","observed_orcids":["https://orcid.org/0000-0002-6197-9860"]},"institutions":[{"id":"https://openalex.org/I867280407","display_name":"The University of Texas Southwestern Medical Center","ror":"https://ror.org/05byvp690","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I867280407"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ann Marie Navar","raw_affiliation_strings":["UT Southwestern Medical Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT Southwestern Medical Center","institution_ids":["https://openalex.org/I867280407"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040589473","display_name":"Steven E. Nissen","orcid":"https://orcid.org/0000-0002-7231-6464","observed_orcids":["https://orcid.org/0000-0002-7231-6464"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven E. Nissen","raw_affiliation_strings":["Cleveland Clinic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051454169","display_name":"Anne Carol Goldberg","orcid":"https://orcid.org/0000-0002-8876-099X","observed_orcids":["https://orcid.org/0000-0002-8876-099X"]},"institutions":[{"id":"https://openalex.org/I204465549","display_name":"Washington University in St. Louis","ror":"https://ror.org/01yc7t268","country_code":"US","type":"education","lineage":["https://openalex.org/I204465549"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anne C. Goldberg","raw_affiliation_strings":["Washington University St. Louis"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Washington University St. Louis","institution_ids":["https://openalex.org/I204465549"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067391389","display_name":"Liam R. Brunham","orcid":"https://orcid.org/0000-0002-3686-3807","observed_orcids":["https://orcid.org/0000-0002-3686-3807"]},"institutions":[{"id":"https://openalex.org/I141945490","display_name":"University of British Columbia","ror":"https://ror.org/03rmrcq20","country_code":"CA","type":"education","lineage":["https://openalex.org/I141945490"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Liam R. Brunham","raw_affiliation_strings":["University of British Columbia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of British Columbia","institution_ids":["https://openalex.org/I141945490"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5093533626","display_name":"Erin Wuerdeman","orcid":"https://orcid.org/0009-0004-2896-2452","observed_orcids":["https://orcid.org/0009-0004-2896-2452"]},"institutions":[{"id":"https://openalex.org/I4405272097","display_name":"NewAmsterdam Pharma (Netherlands)","ror":"https://ror.org/03jdnwh76","country_code":"NL","type":"company","lineage":["https://openalex.org/I4405272097"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Erin Wuerdeman","raw_affiliation_strings":["New Amsterdam Pharma"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"New Amsterdam Pharma","institution_ids":["https://openalex.org/I4405272097"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006314073","display_name":"Annie L Neild","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405272097","display_name":"NewAmsterdam Pharma (Netherlands)","ror":"https://ror.org/03jdnwh76","country_code":"NL","type":"company","lineage":["https://openalex.org/I4405272097"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Annie Neild","raw_affiliation_strings":["New Amsterdam Pharma"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"New Amsterdam Pharma","institution_ids":["https://openalex.org/I4405272097"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015384592","display_name":"Douglas F. Kling","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405272097","display_name":"NewAmsterdam Pharma (Netherlands)","ror":"https://ror.org/03jdnwh76","country_code":"NL","type":"company","lineage":["https://openalex.org/I4405272097"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Douglas Kling","raw_affiliation_strings":["New Amsterdam Pharma"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"New Amsterdam Pharma","institution_ids":["https://openalex.org/I4405272097"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105286197","display_name":"Brian A. Ference","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108499","display_name":"Menarini Group (Italy)","ror":"https://ror.org/02h1wg091","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210108499"]},{"id":"https://openalex.org/I4210151734","display_name":"Fondazione Internazionale Menarini","ror":"https://ror.org/04xzqfk28","country_code":"IT","type":"nonprofit","lineage":["https://openalex.org/I4210151734"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Brian A. Ference","raw_affiliation_strings":["Fondazione Menarini"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fondazione Menarini","institution_ids":["https://openalex.org/I4210108499","https://openalex.org/I4210151734"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Ulrich Laufs","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210125843","display_name":"University Hospital Leipzig","ror":"https://ror.org/028hv5492","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210125843"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Ulrich Laufs","raw_affiliation_strings":["Leipzig University Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leipzig University Hospital","institution_ids":["https://openalex.org/I4210125843"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108693321","display_name":"Maciej Banach","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210122071","display_name":"Medical University of Lodz","ror":"https://ror.org/02t4ekc95","country_code":"PL","type":"education","lineage":["https://openalex.org/I4210122071"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Maciej Banach","raw_affiliation_strings":["Medical University in Lodz"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical University in Lodz","institution_ids":["https://openalex.org/I4210122071"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016139987","display_name":"Roxana Mehran","orcid":"https://orcid.org/0000-0002-5546-262X","observed_orcids":["https://orcid.org/0000-0002-5546-262X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Roxana Mehran","raw_affiliation_strings":["Mount Sinai"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mount Sinai","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091523473","display_name":"Alberico Luigi Catapano","orcid":"https://orcid.org/0000-0002-7593-2094","observed_orcids":["https://orcid.org/0000-0002-7593-2094"]},"institutions":[{"id":"https://openalex.org/I189158943","display_name":"University of Milan","ror":"https://ror.org/00wjc7c48","country_code":"IT","type":"education","lineage":["https://openalex.org/I189158943"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Alberico L. Catapano","raw_affiliation_strings":["University of Milano"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Milano","institution_ids":["https://openalex.org/I189158943"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101777206","display_name":"Michael H. Davidson","orcid":"https://orcid.org/0000-0001-9342-1274","observed_orcids":["https://orcid.org/0000-0001-9342-1274"]},"institutions":[{"id":"https://openalex.org/I4405272097","display_name":"NewAmsterdam Pharma (Netherlands)","ror":"https://ror.org/03jdnwh76","country_code":"NL","type":"company","lineage":["https://openalex.org/I4405272097"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Michael H. Davidson","raw_affiliation_strings":["New Amsterdam Pharma"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"New Amsterdam Pharma","institution_ids":["https://openalex.org/I4405272097"]}]}],"institutions":[],"countries_distinct_count":8,"institutions_distinct_count":13,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4405272097"],"apc_list":{"value":1900,"currency":"USD","value_usd":1900},"apc_paid":{"value":1900,"currency":"USD","value_usd":1900},"fwci":0.5607,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.60797272,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":91,"max":95},"biblio":{"volume":"23","issue":null,"first_page":"101131","last_page":"101131"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13430","display_name":"Lipid metabolism and disorders","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11618","display_name":"Cholesterol and Lipid Metabolism","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/obicetrapib","display_name":"obicetrapib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/heterozygous-familial-hypercholesterolemia","display_name":"heterozygous familial hypercholesterolemia","score":0.9980000257492065},{"id":"https://openalex.org/keywords/ldl-cholesterol-lowering","display_name":"LDL cholesterol lowering","score":0.9509999752044678},{"id":"https://openalex.org/keywords/apolipoprotein-b","display_name":"apolipoprotein B","score":0.8489999771118164},{"id":"https://openalex.org/keywords/lipoprotein-a","display_name":"lipoprotein(a)","score":0.824999988079071},{"id":"https://openalex.org/keywords/non-hdl-cholesterol","display_name":"non-HDL cholesterol","score":0.9139999747276306},{"id":"https://openalex.org/keywords/hdl-cholesterol","display_name":"HDL cholesterol","score":0.9559999704360962},{"id":"https://openalex.org/keywords/lipid-modifying-therapy","display_name":"lipid therapy","score":0.6159999966621399},{"id":"https://openalex.org/keywords/pcsk9-inhibitors","display_name":"PCSK9 inhibitors","score":0.6159999966621399},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.6330000162124634},{"id":"https://openalex.org/keywords/cardiovascular-risk-reduction","display_name":"cardiovascular risk reduction","score":0.6150000095367432},{"id":"https://openalex.org/keywords/triglycerides","display_name":"triglycerides","score":0.6240000128746033}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8901000022888184},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8086000084877014},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.798799991607666},{"id":"https://openalex.org/C2779120738","wikidata":"https://www.wikidata.org/wiki/Q2711291","display_name":"Familial hypercholesterolemia","level":3,"score":0.7542999982833862},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6764000058174133},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6410999894142151},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5687000155448914},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4912000000476837},{"id":"https://openalex.org/C62746215","wikidata":"https://www.wikidata.org/wiki/Q14890615","display_name":"Apolipoprotein B","level":3,"score":0.44020000100135803},{"id":"https://openalex.org/C2780072125","wikidata":"https://www.wikidata.org/wiki/Q28350","display_name":"Lipoprotein","level":3,"score":0.3456000089645386},{"id":"https://openalex.org/C2776104379","wikidata":"https://www.wikidata.org/wiki/Q21112670","display_name":"Lipoprotein(a)","level":4,"score":0.34279999136924744},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.3190999925136566},{"id":"https://openalex.org/C2778270857","wikidata":"https://www.wikidata.org/wiki/Q2723972","display_name":"Lipid profile","level":3,"score":0.2953999936580658},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.27630001306533813},{"id":"https://openalex.org/C141341695","wikidata":"https://www.wikidata.org/wiki/Q2368661","display_name":"Surrogate endpoint","level":2,"score":0.25380000472068787}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.ajpc.2025.101131","doi":"https://doi.org/10.1016/j.ajpc.2025.101131","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ajpc.2025.101131","pdf_url":null,"source":{"id":"https://openalex.org/S4210223033","display_name":"American Journal of Preventive Cardiology","issn_l":"2666-6677","issn":["2666-6677"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","jufo-1","ki-jl-1","norway-1","oarl","poland-20","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Preventive Cardiology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.ajpc.2025.101131","doi":"https://doi.org/10.1016/j.ajpc.2025.101131","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ajpc.2025.101131","pdf_url":null,"source":{"id":"https://openalex.org/S4210223033","display_name":"American Journal of Preventive Cardiology","issn_l":"2666-6677","issn":["2666-6677"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","jufo-1","ki-jl-1","norway-1","oarl","poland-20","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Preventive Cardiology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7131776315","https://openalex.org/W4414439524","https://openalex.org/W1628000978","https://openalex.org/W4413872518","https://openalex.org/W4396639677","https://openalex.org/W7164805239","https://openalex.org/W4407805454","https://openalex.org/W2322015423","https://openalex.org/W7128048321","https://openalex.org/W7128078351"],"abstract_inverted_index":{"Pharmacologic":[0],"Therapy":[1],"BROOKLYN":[2],"examined":[3],"the":[4],"efficacy,":[5],"safety,":[6],"and":[7,28,57,126,128,144,150,155,160,163,166,182,191,210],"tolerability":[8],"of":[9],"obicetrapib":[10,72,91,110,143],"10":[11,73],"mg,":[12],"as":[13,238],"an":[14,134,239],"adjunct":[15,240],"to":[16,70,102,241,273],"maximally":[17,63,242],"tolerated":[18,64,218,243],"lipid-modifying":[19,65,244],"therapies,":[20,245],"in":[21,47,83,95,105,114,119,228,259],"patients":[22,49,260,267],"with":[23,42,55,93,112,171,196,219,253,261,268,279],"heterozygous":[24],"familial":[25],"hypercholesterolemia":[26],"(HeFH)":[27],"suboptimal":[29],"LDL-C":[30,59,176,248,276],"control.":[31],"This":[32],"was":[33,133,216],"a":[34,84],"phase":[35],"3,":[36],"randomized,":[37],"double-blind,":[38],"placebo-controlled":[39],"trial":[40],"NCT05425745":[41],"1":[43],"year":[44],"follow":[45],"up":[46],"354":[48],"across":[50],"70":[51],"sites.":[52],"Participants":[53],"(n=354)":[54],"HeFH":[56,269],"fasting":[58],"\u00b370":[60],"mg/dL":[61],"taking":[62],"therapies":[66],"were":[67,147],"randomly":[68],"assigned":[69],"receive":[71],"mg":[74],"or":[75,224,232],"matching":[76],"placebo":[77,94,113],"orally":[78],"daily":[79],"for":[80,142,266],"52":[81],"weeks":[82],"2:1":[85],"ratio.":[86],"Study":[87],"primary":[88],"endpoint":[89],"assessed":[90],"compared":[92,111,170,195],"LS":[96],"mean":[97,175,200],"percent":[98,115],"change":[99],"from":[100,117],"baseline":[101,118,138],"week":[103],"12":[104],"LDL-C.":[106],"Secondary":[107],"endpoints":[108],"included":[109],"changes":[116,227],"Apo":[120,131],"B,":[121],"nonHDL-C,":[122],"HDL-C,":[123],"total-C,":[124],"Lp(a),":[125],"TG,":[127],"safety":[129],"measures;":[130],"A1":[132],"exploratory":[135],"endpoint.":[136],"Mean":[137],"lipoprotein":[139],"lipid":[140],"levels":[141],"placebo,":[145,172,197],"respectively,":[146],"LDL-C:":[148],"123.4":[149],"119.9":[151],"mg/dL;":[152,157,162],"ApoB:":[153],"107.2":[154],"105.3":[156],"non-HDL-C:":[158],"148.4":[159],"146.7":[161],"HDL-C:":[164],"53.2":[165],"50.2":[167],"mg/dL.":[168],"Obicetrapib,":[169,237],"significantly":[173,198],"reduced":[174,199],"-36.3%":[177],"at":[178,184,250],"day":[179,185,189,192,251,257],"84":[180,190,252],"(P<0.0001)":[181],"-41.5%":[183],"365":[186,258],"(P<0.0001).":[187],"On":[188],"365,":[193],"obicetrapib,":[194],"ApoB":[201],"-24.4%,":[202],"-25.8%;":[203],"non-HDL-C":[204],"-34.5%,":[205],"-37.5%;":[206],"Lp(a)":[207],"-45.9%,":[208],"-54.3%;":[209],"increased":[211],"HDL-C":[212],"138.7%,121.4%,":[213],"respectively.":[214],"Obicetrapib":[215,263],"well":[217],"no":[220],"serious":[221],"adverse":[222],"events":[223],"clinically":[225],"significant":[226,247],"vital":[229],"signs,":[230],"electrocardiograms,":[231],"other":[233],"clinical":[234],"laboratory":[235],"values.":[236],"produced":[246],"lowering":[249],"sustained":[254],"effect":[255],"through":[256],"HeFH.":[262],"holds":[264],"promise":[265],"who":[270],"are":[271],"unable":[272],"attain":[274],"their":[275],"treatment":[277],"targets":[278],"available":[280],"lipid-lowering":[281],"agents.":[282]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2025-10-10T00:00:00"}